Our Founder and CEO, Dr Ruchi Sharma is driven by her passion for taking the benefits of research, and applying them to products and technology in order to make a significant and positive difference in the real world. Alongside over ten years experience in stem cell research, physiology, and biotechnology, Dr Sharma obtained a PhD from the world-renowned Roslin Institute at the University of Edinburgh, followed by a post-doctorate in the exciting field of cellular reprogramming at the University of Cambridge. With a firm focus on collaboration, Dr Sharma firmly believes that together, we can create a better world. Find out more
Femi is a graduate of Warwick University. He is a seasoned molecular biologist with years of experience in the biotechnology industry. Femi’s area of interest includes whole transcriptome sequencing and bioinformatic analysis, genotyping, semi quantitative and quantitative PCR. He also holds a MSc in cancer cell and molecular biology from the
University of Leicester.
A Professor of Tissue Engineering at the University of Edinburgh, co-Founder and Director Dr David Hay has earned a long-standing reputation for his work in stem cell biology and hepatocyte differentiation. Dr Hay believes that a trans-disciplinary approach is needed to solve the failings that currently exist in the cell microenvironment. Dr Hay is actively involved in the translation of stem cell derived hepatocytes into scalable manufacturing processes, by defining culture conditions and developing physiologically relevant models. Find out more
Sunil joined Stemnovate’s board recently and brings the wealth of experience as a serial entrepreneur. He cofounded O2h Ventures which involves seeding drug discovery, academic in-licensing, and biotechnology incubation. Sunil holds MBA degree from the Cambridge University.
Sumon is the R&D Scientist at Stemnovate Ltd. His principle expertise lies in iPSC- differentiation into specialized cell types and in vitrocell-based tissue engineering. Sumon is responsible for the in-house generation of Hepatocytes and Cardiomyocytes for drug screening cell-based assays and Liver-on-chip integration. Sumon holds a PhD in Molecular Medicine at the University of Göttingen,Germany, and MRes in Cardiovascular Sciences at the University of Manchester.
Varindra has obtained his Bachelor of Engineering in Electronics from Regional Engineering College Rourkela and Master of Technology in Electronics and Communication Engineering from Indian Institute of Technology, Varanasi. Subsequently after working across various electronics design companies, he joined and completed his Ph.D. from the University of Nottingham. His research interest lies in machine learning, electronics design, sensor design, IOT systems, wearable electronics, electromagnetic and antenna design etc and has published some papers in reputed journals.
Vidisha Krishnan is developing the assays for in vitro ADME at Stemnovate. She obtained PhD from the University of Sussex working on the Bacillus thuringiensis proteins that preferentially acted on human hepatic cancer cells.